Drug detail

Temozolomide

Structured drug profile (research browsing)

Data: Live structured evidence (Supabase)

Limitations & build flags

Read-only structured navigator
No clinical outcome benefit inferred
Trial presence does not imply success
Drug identity may require normalization
Terminated/withdrawn trials must remain visible

Narrative summary

Source-separated structured row for analyst orientation — requires clinical review before operational use.

Context string

manual_seed

Related targets

ABCC3 ABCC4 DNA

Evidence source badges

Badges encode provenance hints; each item requires oncology review.

Appears in source landscapeRequires oncology review

Linked research signals

Signals list: Live structured evidence (Supabase)

Repurposing research signal · Temozolomide · v0.1

Deterministic research signal for Temozolomide. Aggregate template score 40 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, clinicaltrials.gov, repodb. Negative or caution-bearing registry/repoDB context is present — read components in raw_json. Missing relative to the Phase 8A template: Open Targets disease–target evidence. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.